FY2026 Earnings Forecast for ARWR Issued By Leerink Partnrs

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a report released on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($0.92) per share for the year, down from their prior forecast of $0.10. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

Other equities analysts also recently issued research reports about the company. Piper Sandler decreased their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup decreased their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. B. Riley reaffirmed a “buy” rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $15.11 on Thursday. Arrowhead Pharmaceuticals has a twelve month low of $14.23 and a twelve month high of $30.41. The business’s 50 day moving average price is $18.66 and its two-hundred day moving average price is $19.98. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market cap of $2.07 billion, a PE ratio of -2.92 and a beta of 0.92.

Insider Buying and Selling

In related news, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now owns 36,740 shares of the company’s stock, valued at $734,800. This represents a 7.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 301,730 shares of company stock valued at $5,352,844 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the business. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $38,000. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $49,000. Van ECK Associates Corp boosted its holdings in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares in the last quarter. KBC Group NV boosted its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares in the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $137,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.